Context Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Context Therapeutics (CNTX).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

1S.Buy

8Buy

Consensus RatingBuy# Analysts9Avg. Consensus PT$6Upside to Avg. PT+2151.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 16, 2026	Maxim Group	Jason McCarthy	PT Cut	Buy	$8→$4
Mar 24, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9
Mar 24, 2026	Guggenheim	Paul Jeng	Maintained	Buy	$5
Mar 24, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$4→$7
Dec 22, 2025	Jones Trading	Soumit Roy	Initiate	Buy	$7
Nov 6, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9
Nov 6, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$4→$5
Oct 16, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9
Oct 2, 2025	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
Sep 18, 2025	Guggenheim	Paul Jeng	Initiate	Buy	$5
Aug 7, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9
Aug 7, 2025	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$5→$4
Jun 26, 2025	Piper Sandler	Biren Amin	PT Cut	Overweight	$5→$4
May 8, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9
Apr 29, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9
Apr 21, 2025	William Blair	Matt Phipps	Initiate	Outperform	—
Apr 9, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9
Mar 21, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$5
Mar 21, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9
Jan 15, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$9

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $8 to $4.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.

Benzinga Newsdesk

This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

PRO
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

Benzinga Newsdesk

Context Therapeutics Inc

Context Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

PRO
Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

PRO
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PRO
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

PRO
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target

People Also Watch

People Also Watch

Context Therapeutics Inc

Context Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

PROGuggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

PROPiper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

PROJones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

PROD. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target

People Also Watch

People Also Watch

PRO
Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

PRO
Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

PRO
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

PRO
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

PRO
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target